TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12020302

Group type: EXPERIMENTAL
Intervention: CEEs, 0.625 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.625 mg/d and MPA, 2.5 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.45 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.45 mg/d and MPA, 2.5 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.45 mg/d and MPA, 1.5 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.3 mg/d
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEEs, 0.3 mg/d and MPA, 1.5 mg/d
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 9792383

Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 24
Study: 7712301

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 4 weeks) + Amoxycillin (1 g three times daily for 2 weeks) + Metronidazole (1 g daily for 2 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Omeprazole + Antibiotics
Number of subjects: 37
Study: 2541397

Group type: EXPERIMENTAL
Intervention: NTM skin test antigens
Number of subjects: 11

Group type: COMPARATOR
Intervention: Purified protein derivative (control)
Number of subjects: 11
Study: 238790

Group type: EXPERIMENTAL
Intervention: Clemastine (1 mg b.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlorpheniramine (4 mg b.d.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clemastine elixir (0.5 mg b.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlorpheniramine syrup (2 mg b.d.)
Number of subjects: 100
Study: 29678585

Group type: COMPARATOR
Intervention: Metal‐ceramic (MC, control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lava Zirconia (LZ, bi‐layered)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lava Plus (LM, monolithic)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VITA In‐Ceram YZ (YZ, bi‐layered)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IPS e‐max ZirCAD (ZZ, bi‐layered)
Number of subjects: 50
Study: 28179916

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Calcium-Enriched Mixture (CEM) cement
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both MTA and CEM cement
Number of subjects: 47
Study: 25143342

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) containing 2.5 mg iron as NaFeEDTA
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) containing 12.5 mg iron as ferrous fumarate
Number of subjects: 115

Group type: COMPARATOR
Intervention: Micronutrient powder without iron (control)
Number of subjects: 115
Study: 23706947

Group type: EXPERIMENTAL
Intervention: DEX implant plus laser treatment
Number of subjects: 253

Group type: COMPARATOR
Intervention: Laser treatment alone
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 253
Study: 20568447

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese herbs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 18227366

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride therapy with smoking counseling
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Low BDI scores
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms
Number of subjects: 245
Study: 16607469

Group type: EXPERIMENTAL
Intervention: Subthalamic Nucleus Deep Brain Stimulation (STN‐DBS)
Number of subjects: 15
Study: 14667957

Group type: EXPERIMENTAL
Intervention: Eptifibatide + Unfractionated Heparin (UFH)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eptifibatide + Enoxaparin
Number of subjects: 14
Study: 11700258

Group type: EXPERIMENTAL
Intervention: GnRHA plus low-dose add-back estrogen-progestin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 9136842

Group type: EXPERIMENTAL
Intervention: Pancreatin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intraileal nutrient perfusion
Number of subjects: 26
Study: 7870745

Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg/day in three oral doses)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg/day in three oral doses)
Number of subjects: 2
Study: 3367336

Group type: EXPERIMENTAL
Intervention: Nipple stimulation contraction stress test
Number of subjects: 186

Group type: COMPARATOR
Intervention: Nonstress test
Number of subjects: 186
Study: 1958436

Group type: EXPERIMENTAL
Intervention: Standard nicardipine (STD) 30 mg three times daily for 28 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sustained release nicardipine (SR) 60 mg twice daily for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 616212

Group type: EXPERIMENTAL
Intervention: CO inhalation (1100 ppm CO-air mixture)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air breathing
Number of subjects: 14
Study: 30216734

Group type: EXPERIMENTAL
Intervention: Hall technique (HT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional restoration (CR)
Number of subjects: 132
Study: 27591965

Group type: EXPERIMENTAL
Intervention: Digital alteration disclaimer label
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Pre-exposure message about digital alteration
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combination of disclaimer label and pre-exposure message
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 280
Study: 26338956

Group type: EXPERIMENTAL
Intervention: Ivabradine at 7.5 mg twice daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 22
Study: 23407644

Group type: EXPERIMENTAL
Intervention: GSK424887
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram (positive control)
Number of subjects: 0
Study: 21682858

Group type: EXPERIMENTAL
Intervention: On-site Biostatistics course (3.5 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: On-line Biostatistics course (3.5 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: On-site Research Ethics course (3.5 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: On-line Research Ethics course (3.5 weeks)
Number of subjects: 58
Study: 18550399

Group type: EXPERIMENTAL
Intervention: M6G 30 mg/70 kg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: M6G (10 mg/70 kg and 20 mg/70 kg)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 170
Study: 17803344

Group type: EXPERIMENTAL
Intervention: Ulinastatin therapy (30,000 U/kg/day for 3 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: IVIG therapy (1 g/kg/dose)
Number of subjects: 27
Study: 14729733

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg orally every 12 h for a total of six doses
Number of subjects: 11
Study: 11238753

Group type: EXPERIMENTAL
Intervention: 16 g dietary fiber (wheat bran) supplementation for 1 month
Number of subjects: 26

Group type: COMPARATOR
Intervention: Soy protein supplementation (longer-term for 1 month or short-term for 4 days)
Number of subjects: 26
Study: 9720743

Group type: EXPERIMENTAL
Intervention: glycl‐L‐glutamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: isonitrogenous mixture of non‐essential amino acids
Number of subjects: 34
Study: 8054116

Group type: EXPERIMENTAL
Intervention: Groups led by content experts
Number of subjects: 211

Group type: COMPARATOR
Intervention: Groups led by non-experts
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: All groups (expert and non-expert)
Number of subjects: 211
Study: 2567903

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate ('Augmentin') alone (36 patients)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Myringotomy plus placebo (35 patients)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Augmentin plus myringotomy (34 patients)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Myringotomy plus augmentin (34 patients)
Number of subjects: 105
Study: 30897584

Group type: EXPERIMENTAL
Intervention: ONO‐8539 (450 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30720005

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Primary Open-Angle Glaucoma (POAG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preperimetric Glaucoma (PPG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 120
Study: 28086976

Group type: EXPERIMENTAL
Intervention: Tailored program (workshop for GPs, educational materials, reminders for patients, implementation action plans)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tailored program
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273
Study: 27549500

Group type: EXPERIMENTAL
Intervention: Walking at preferred speed
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking slower than preferred speed
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking faster than preferred speed
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: First test of PCI estimation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking at varying distances (50m, 100m, 150m)
Number of subjects: 50
Study: 23940231

Group type: EXPERIMENTAL
Intervention: Standard care plus the 4-week yoga intervention (YOCAS program: pranayama, 16 Gentle Hatha and Restorative yoga asanas, and meditation; 2 sessions per week of 75 minutes each)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 410
Study: 21458058

Group type: EXPERIMENTAL
Intervention: Midlevel providers (200 mg mifepristone followed by 800 μg misoprostol vaginally 2 days later)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Doctors (200 mg mifepristone followed by 800 μg misoprostol vaginally 2 days later)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Midlevel providers
Number of subjects: 1077
Study: 19922879

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 443

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Insulin detemir (twice-daily)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 443
Study: 17019296

Group type: EXPERIMENTAL
Intervention: Moderate NaHCO3 intake (0.3 g x kg(‐1) x d(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High NaHCO3 intake (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 12762604

Group type: EXPERIMENTAL
Intervention: Concise sealant (3M)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dyract seal (Dentsply DeTrey)
Number of subjects: 22
Study: 11093490

Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation (group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Off-pump beating heart revascularization (group B)
Number of subjects: 108
Study: 8959154

Group type: EXPERIMENTAL
Intervention: Intravenous bacille Calmette‐Guérin (BCG) vaccination
Number of subjects: 30
Study: 1572703

Group type: EXPERIMENTAL
Intervention: Glass fibre splinting bandages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-glass bandages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaster-of-Paris bandages
Number of subjects: 0
Study: 3911963

Group type: EXPERIMENTAL
Intervention: suprofen syrup
Number of subjects: 115

Group type: COMPARATOR
Intervention: paracetamol syrup
Number of subjects: 115
Study: 31332929

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring system
Number of subjects: 19
Study: 30233184

Group type: EXPERIMENTAL
Intervention: Victimization (physical or sexual assault)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Posttraumatic stress disorder (PTSD) diagnosis
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Depressive symptoms severity
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Suicide risk
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Physical health status
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Path analysis of PTSD and violent victimization
Number of subjects: 703
Study: 26644241

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg, oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26535762

Group type: EXPERIMENTAL
Intervention: Single-item self-rated mental health (SRMH) measure
Number of subjects: 239

Group type: COMPARATOR
Intervention: Davidson Trauma Scale for PTSD
Number of subjects: 239

Group type: COMPARATOR
Intervention: Edinburgh Postnatal Depression Scale for depression
Number of subjects: 239
Study: 24041860

Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg-2 ml)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg-2 ml)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (2 ml serum physiologic)
Number of subjects: 75
Study: 19804945

Group type: EXPERIMENTAL
Intervention: Smokers with low confidence to control abstinence-induced symptoms facing internal stimuli (e.g., feeling depressed)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Smokers with low confidence to control abstinence-induced symptoms facing external stimuli (e.g., during a celebration)
Number of subjects: 576
Study: 17976891

Group type: EXPERIMENTAL
Intervention: 15:2 CPR protocol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30:2 CPR protocol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of 15:2 and 30:2 CPR protocols
Number of subjects: 26
Study: 16153777

Group type: EXPERIMENTAL
Intervention: CB pain management training (PMT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Education/attention control condition (self-care management, SCM)
Number of subjects: 158
Study: 12576897

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (20 to 30 U, approximately 0.3 U/kg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 111
Study: 10494574

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg administered twice daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7566521

Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 1952269

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 62

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study: 6988945

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg before operation and 100 mg daily for 5 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Doxycycline (adequate prophylaxis in 159 patients)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Doxycycline (preoperatively for intra-abdominal infection in 11 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No prophylaxis (incomplete or no prophylaxis in 12 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Non-contaminated operations
Number of subjects: 118

Group type: COMPARATOR
Intervention: Contaminated operations
Number of subjects: 118
Study: 30814561

Group type: EXPERIMENTAL
Intervention: Visual observation of a mannequin body from a first-person perspective
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conditions including touch to participants' own, unseen body
Number of subjects: 80

Group type: COMPARATOR
Intervention: Slow, affective touch on participants' own, unseen body
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fast, non-affective touch on participants' own, unseen body
Number of subjects: 80
Study: 28252371

Group type: EXPERIMENTAL
Intervention: Twice‐yearly routine restaurant inspection
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard once‐yearly routine inspection
Number of subjects: 151
Study: 25747719

Group type: EXPERIMENTAL
Intervention: Children's Hospital at Montefiore Joining Academics and Movement (CHAM JAM) - an audio CD with 10-minute aerobic activities led by teachers three times a day.
Number of subjects: 988

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 988
Study: 22958078

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Tadalafil 5.0 mg
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study: 22013798

Group type: EXPERIMENTAL
Intervention: Wuzhi Capsule (WC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (Tac + MMF + Pred)
Number of subjects: 73
Study: 18286351

Group type: EXPERIMENTAL
Intervention: Low-dose steroid therapy (prednisolone 0.4 mg/kgBW/day, tapered to 5-10 mg/day over 24 months)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-dose steroid therapy (prednisolone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (dipyridamole or zilazep hydrochloride 150 or 300 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (dipyridamole or zilazep hydrochloride)
Number of subjects: 48
Study: 17132537

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (800 microg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14529881

Group type: EXPERIMENTAL
Intervention: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A, n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal CsA dose (10 mg/kg/day) without daclizumab (group B, n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal CsA dose (10 mg/kg/day) without daclizumab (group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 11113421

Group type: EXPERIMENTAL
Intervention: sublingual estradiol 17beta
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 1532534

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25-10 mg/day
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg/day + Hydrochlorothiazide 12.5 mg/day
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5 mg/day
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Cilazapril + Hydrochlorothiazide
Number of subjects: 4500
Study: 3921597

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg NAL infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg NAL infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg NAL infusion
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: All doses of NAL
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Higher doses of NAL
Number of subjects: 4
Study: 31664143

Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1064
Study: 30293878

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W) or 150 mg Q2W
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 655
Study: 27687342

Group type: EXPERIMENTAL
Intervention: Multisource feedback with monthly coaching meetings
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no monthly coaching meetings)
Number of subjects: 28
Study: 24652690

Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MRI
Number of subjects: 360

Group type: COMPARATOR
Intervention: ECCM-MRI
Number of subjects: 360

Group type: COMPARATOR
Intervention: CE-CT
Number of subjects: 360
Study: 22227740

Group type: EXPERIMENTAL
Intervention: Pre-exposure to the to-be-conditioned context (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unrelated virtual environment (control group, n = 20)
Number of subjects: 40
Study: 21189213

Group type: EXPERIMENTAL
Intervention: Core weave stitch with three, five, or seven throws
Number of subjects: 21

Group type: COMPARATOR
Intervention: Krackow stitch with three, five, or seven throws
Number of subjects: 21
Study: 18796350

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (5 g) before each chemotherapy course and magnesium subcarbonate (500 mg) three times per day orally during treatment intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo instead of magnesium salts
Number of subjects: 40
Study: 15812765

Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine
Number of subjects: 137

Group type: COMPARATOR
Intervention: No prophylactic brimonidine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in hypertensive patients
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in diabetic patients
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in patients on anticoagulant or antiplatelet treatment
Number of subjects: 137
Study: 12192690

Group type: EXPERIMENTAL
Intervention: Chest compressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilatory volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biphasic waveform defibrillators and automated external defibrillators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-catecholaminergic vasopressors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary reperfusion strategies
Number of subjects: 0